Stevan Jovanovich, Ph.D.
Founder & CEO
Dr. Stevan Jovanovich is the President/CEO of both S2 Genomics, Inc., and its parent Silicon Valley Scientific, Inc. S2 Genomics was founded in 2016 to develop integrated sample preparation systems for genomics focusing on tissue samples. Previously, he was President/CEO/Founder and CTO of IntegenX, Inc., a Silicon Valley Scientific, Inc. spinout. IntegenX is the global leader in rapid human identification. Dr. Jovanovich is a co-founder and Director of Functional Biosciences, Inc., a leading CLIA DNA sequencing laboratory.
Before co-founding Silicon Valley Scientific, Inc., Dr. Jovanovich was Vice President of Global Research at Amersham Biosciences. Prior positions include Science Director at Amersham Biosciences Sunnyvale, Manager of Advanced Research at Molecular Dynamics, Staff Scientist at Lawrence Berkeley National Laboratory, Director of Microbiology at AbTox Inc, founder of Molecular Solutions, and Applications Programmer at the Institute for Defense Analyses.
He is author of 28 peer-reviewed papers and reviews, an inventor on over 70 patents, and has automated life science workflows since 1987. He holds Bachelor of Science degrees in Physics and Life Sciences from MIT, a Ph.D. in Microbiology from University of California at Davis with a minor in Molecular Biology, and a Certificate in bject-Oriented Programming from the University of California Santa Cruz Extension.
Peter Wagner, Ph.D.
Dr. Peter Wagner is a seasoned biotech executive with a 20-year track record of leadership and innovative technology implementation and commercialization in the life science tool and diagnostics sectors. His main interest is on white space product development, startup entrepreneurship, strategic business development and manufacturing/supply chain scale-up operations. Dr. Wagner has led and managed multi-disciplinary teams in challenging environments. His core scientific expertise centers at the interface of biochemistry and materials/surface science. As a cofounder of S2 Genomics, he serves on its Board as well as provides various operations and business development assistance on a part-time basis. Together with Dr. Jovanovich, he co-invented the technology that powers S2 Genomics.
Before co-founding S2 Genomics, Dr. Wagner established Coincident Biosciences, a product development and operations consulting firm, and for the past 16 years prior, he was CEO/CTO at Zyomyx Inc., a protein chip and cell-based diagnostics leader he cofounded in 1998. Prior to Zyomyx, Dr. Wagner was an Alexander-von-Humboldt Fellow at the Beckman Center for Molecular and Genetic Medicine, Stanford University.
Named World Economic Forum Technology Pioneer, Dr. Wagner is an inventor on over 65 patents, co-authored 38 peer-reviewed publications and presented at over 100 scientific conferences. He holds two M.S. degrees in Biochemistry and Chemistry from the Universities FU Berlin and Stuttgart-Hohenheim, Germany, and a Ph.D. in Single Molecule Biophysics and Nanoscale Surface Science from the Swiss Federal Institute of Technology, Zurich, Switzerland.
Michael Wiley, J.D., CPA, joined the board in 2020. He currently heads up Corporate Affairs at Guardant Health, a public diagnostic laboratory in oncology that he helped found in 2012. Michael was Guardant’s Chief Financial Officer until mid 2016 and its Chief Legal Officer until May 2020. Prior to joining Guardant, Michael worked as CFO at Voyage Medical, a medical device company in the cardiovascular space backed by Kleiner Perkins, Three Arch Partners and Abbott. Before Voyage, Michael was VP of Finance at IntegenX (fka Microchip Biotechnologies) under Dr. Jovanovich. Earlier in his career, Michael was a corporate attorney at Venture Law Group (later Heller Ehrman) and acted as in-house associate counsel for Novell where he focused on intellectual property and employment issues. Before receiving a JD from the J. Reuben Clark Law School at Brigham Young University, Michael worked for KPMG as a tax account. In addition to his current work at Guardant and his board membership with S2 Genomics, Michael sits on the board of LeGrande Corporation (a personalized health company) and is an advisor to Farapulse, Inc. (a medical device company in the cardiovascular space backed by Boston Scientific).
Michael J. Finney, Ph.D.
Dr. Finney is a board director or advisor to multiple biotechnology companies, with an emphasis on companies that supply fundamental technologies. He currently serves on the board of directors of 7 privately held companies, plus one public company, Vaxart (VXRT), where he also served as CEO for two years. He co-founded and serves on the board of The Genome Partnership, a nonprofit that runs AGBT, the leading annual conference on genomic technology. Previously, he co-founded MJ Research, a manufacturer of instruments used in genomic technology. The bootstrapped company was sold to Bio-Rad in 2004.
Shannon Hall is a co-founder, and investor, an advisor, and a board member of S2 Genomics. She has been developing the tools that drive advances in life science research for over twenty-six years.